Gout, a painful arthritis caused by uric acid buildup, triggers flare-ups worsened by genetics, diet, alcohol, or medication.

ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...

Patients who use NSAIDs for paradoxical gout flare prevention when starting allopurinol demonstrate greater risk for adverse ...

Among patients in the US with gout, nearly 72% of disease flares went unreported or were pretreated/prevented by patients. Gout flares among adults in the United States are significantly underreported ...

Man on bed with pillow embrace foot with painful swollen gout inflammation Researchers compared the time to complete resolution of acute gout flare between early and late allopurinol initiation. Among ...

One day you wake up feeling fine, and the next day you suddenly can't even walk. For most people, the pain is unbearable and ...

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular diseaseHANGZHOU, China--(BUSINESS WIRE)--Atom Therapeutics, a clinical ...

Clinical efforts to get patients with a history of gout to reach specific target serum urate (SU) levels less than either 5 or 6 mg/dL could prevent the great majority of gout flares and ...

Gout is a painful form of arthritis caused by high uric acid levels that form sharp crystals in the joints, leading to swelling, stiffness, and intense discomfort. While genetics and medical ...

Gout patients frequently have a number of comorbidities, including obesity, hypertension, high serum lipid and cholesterol levels, kidney disease, diabetes, and cardiovascular disease. [2,7,19–21] Due ...

"Acute Gout Flare Market 2034 by DelveInsight"The report analyzes the existing treatment practices and unmet medical requirements in Acute Gout Flare. It evaluates the market potential and identifies ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...